A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody

• DOI: 10.1016/j.imlet.2021.10.006
• Publication Date: 2021-10-27T00:13:02Z
• Authors: Eun Ji Lee; Gun-Young Jang; Sung Eun Lee; Ji won Lee; Hee Dong Han; Yeong-Min Park; Tae Heung Kang
• Keywords: CD80; CD86; Cancer Immunotherapy

Immune checkpoint inhibitors (ICIs), including programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) and cytotoxic T-lymphocyte-associated 4 have shown promising cancer clinical outcomes. However, IC therapy has low patient response rates (10%–15%). Thus, ICIs sufficient antigen combinations into the tumor microenvironment (TME) is important to produce strong tumor-specific adaptive immune responses. Mice were treated with cisplatin, human cells exposed inflammatory cytokines, confirm increased PD-L1 major histocompatibility complex (MHC) I expression by or dendritic cells. TC-1, CT26, B16-F1, B16-F10 cells, bone marrow-derived interferon (IFN)-β, IFN-γ, necrosis factor-α identify molecular mechanisms underlying MHC upregulation, examine I, CD40, CD80, CD86, levels, respectively. For synergistic combination therapy, αPD-L1 monoclonal antibody (mAb) covalently linked long E7 peptide was generated. Chemotherapy shifted TME express high resulting in targeted ICI cargo delivery enhanced generation activation of antigen-specific T Synergistic effects vaccination blockade demonstrated using an anti-PD-L1 mAb conjugated peptide.